Trial Profile
Research evaluation to study individuals who show thromboxane or P2Y12 receptor resistance
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptifibatide (Primary) ; Heparin
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- 01 Feb 2013 Planned number of patients changed from 600 to 1200 as reported by ClinicalTrials.gov.
- 19 Jul 2007 Status changed from recruiting to discontinued. Sponsor support withdrawn.
- 21 Jul 2006 New trial record.